

Juan J Lasarte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7966778/publications.pdf>

Version: 2024-02-01

168
papers

7,641
citations

50170

46
h-index

69108

77
g-index

175
all docs

175
docs citations

175
times ranked

10697
citing authors

#	ARTICLE	IF	CITATIONS
1	TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity. <i>Cancer Letters</i> , 2022, 528, 45-58.	3.2	7
2	CAR-T Cells for the Treatment of Lung Cancer. <i>Life</i> , 2022, 12, 561.	1.1	8
3	Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy. <i>OncoImmunology</i> , 2022, 11, 2070337.	2.1	9
4	Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
5	Impact of tumor microenvironment on adoptive T cell transfer activity. <i>International Review of Cell and Molecular Biology</i> , 2022, , 1-31.	1.6	8
6	Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy. <i>Cancer Letters</i> , 2021, 499, 279-289.	3.2	7
7	Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma. <i>BioMed Research International</i> , 2021, 2021, 1-9.	0.9	8
8	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. <i>Emerging Microbes and Infections</i> , 2021, 10, 1931-1946.	3.0	11
9	The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes. <i>British Journal of Cancer</i> , 2021, 124, 1138-1149.	2.9	14
10	Searching for Peptide Inhibitors of T Regulatory Cell Activity by Targeting Specific Domains of FOXP3 Transcription Factor. <i>Biomedicines</i> , 2021, 9, 197.	1.4	3
11	SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. , 2021, 9, e001496.		42
12	Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential. <i>Frontiers in Immunology</i> , 2021, 12, 652160.	2.2	12
13	The TGF- β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. <i>Cancers</i> , 2021, 13, 3248.	1.7	37
14	Olfactory Characterization and Training in Older Adults: Protocol Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 757081.	1.7	4
15	Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants. , 2021, 9, e003351.		14
16	The involvement of <sc>ADAM</sc> 10 in acantholysis in mucocutaneous pemphigus vulgaris depends on the autoantibody profile of each patient. <i>British Journal of Dermatology</i> , 2020, 182, 1194-1204.	1.4	17
17	Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. <i>Nature Cancer</i> , 2020, 1, 75-85.	5.7	68
18	Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3397.	1.7	17

#	ARTICLE	IF	CITATIONS
19	Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. <i>Cancers</i> , 2020, 12, 3169.	1.7	10
20	Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens. , 2020, 8, e000704.		8
21	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
22	Analysis of copy number alterations reveals the lncRNA ALAL-1 as a regulator of lung cancer immune evasion. <i>Journal of Cell Biology</i> , 2020, 219, .	2.3	36
23	Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. <i>Nature Medicine</i> , 2019, 25, 1073-1081.	15.2	125
24	FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells. <i>Anticancer Research</i> , 2019, 39, 5369-5374.	0.5	5
25	Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses. <i>Molecular Therapy</i> , 2019, 27, 1892-1905.	3.7	28
26	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN- β . <i>Journal of Immunology</i> , 2019, 203, 696-704.	0.4	6
27	Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1098-1105.	0.2	15
28	PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. <i>Blood</i> , 2019, 133, 2401-2412.	0.6	54
29	MA17.11 High Sensitivity to PD-1 Blockade Therapy After Ld1 Depletion in KRAS-Driven Lung Cancer Through CD8+/CD3+ Tumor Infiltration and PD-L1 Induction. <i>Journal of Thoracic Oncology</i> , 2019, 14, S320.	0.5	0
30	Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies. <i>Frontiers in Immunology</i> , 2019, 10, 2990.	2.2	14
31	Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 379-393.	2.0	100
32	The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer. <i>Oncolmmunology</i> , 2018, 7, e1409321.	2.1	15
33	Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms. <i>Haematologica</i> , 2018, 103, 1065-1072.	1.7	10
34	MA06.03 PD-1 and Id-1 Combined Blockade Impacts Tumor Growth and Survival Through PD-L1 Expression and Tumor Infiltration by Immune-Related Cells. <i>Journal of Thoracic Oncology</i> , 2018, 13, S375-S376.	0.5	0
35	The HDAC inhibitor belinostat enhances the anti-tumor efficacy of immune checkpoint inhibitors in a murine hepatocellular carcinoma model. <i>Journal of Hepatology</i> , 2018, 68, S677.	1.8	2
36	Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice. <i>Frontiers in Immunology</i> , 2018, 9, 68.	2.2	14

#	ARTICLE	IF	CITATIONS
37	Effect of anti-PD-1 and anti-Id-1 combo on tumor response and survival in lung cancer.. Journal of Clinical Oncology, 2018, 36, 12085-12085.	0.8	0
38	Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. Cancer Research, 2017, 77, 3672-3684.	0.4	99
39	Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nature Communications, 2017, 8, 15424.	5.8	109
40	A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis. Cancer Discovery, 2017, 7, 694-703.	7.7	160
41	Therapeutic blockade of Foxp3 in experimental breast cancer models. Breast Cancer Research and Treatment, 2017, 166, 393-405.	1.1	21
42	Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10â€“Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells. Diabetes, 2017, 66, 448-459.	0.3	57
43	Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance. Frontiers in Immunology, 2017, 8, 594.	2.2	12
44	Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA). PLoS ONE, 2017, 12, e0185169.	1.1	29
45	IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. Oncotarget, 2017, 8, 2659-2671.	0.8	41
46	Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. Oncotarget, 2017, 8, 71709-71724.	0.8	27
47	MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells. Oncotarget, 2016, 7, 23182-23196.	0.8	58
48	Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral Vaccine. PLoS ONE, 2016, 11, e0161216.	1.1	13
49	Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. Journal of Medical Virology, 2016, 88, 843-851.	2.5	3
50	Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop. Cancer Research, 2016, 76, 2863-2867.	0.4	4
51	T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates. Gene Therapy, 2016, 23, 753-759.	2.3	7
52	Targeting inhibition of Foxp3 by a CD28 2â€²-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. Biomaterials, 2016, 91, 73-80.	5.7	43
53	Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination. OncoImmunology, 2016, 5, e1075113.	2.1	20
54	Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15006.	1.8	15

#	ARTICLE	IF	CITATIONS
55	Immune monitoring of immunosuppression withdrawal of liver transplant recipients. <i>Transplant Immunology</i> , 2015, 33, 110-116.	0.6	25
56	Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxlIT motif of calcineurin binding partners. <i>Science Signaling</i> , 2015, 8, ra63.	1.6	22
57	Genetic Basis for Clinical Response to CTLA-4 Blockade. <i>New England Journal of Medicine</i> , 2015, 372, 783-783.	13.9	85
58	Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation. <i>Journal of Immunology</i> , 2015, 195, 3180-3189.	0.4	44
59	Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells. <i>Cancer Cell</i> , 2015, 28, 281-283.	7.7	11
60	Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance. <i>Liver Transplantation</i> , 2013, 19, 937-944.	1.3	87
61	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 81-88.	1.8	816
62	Searching for the Achilles Heel of FOXP3. <i>Frontiers in Oncology</i> , 2013, 3, 294.	1.3	22
63	A Fusion Protein between Streptavidin and the Endogenous TLR4 Ligand EDA Targets Biotinylated Antigens to Dendritic Cells and Induces T Cell Responses <i>In Vivo</i> . <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	15
64	Helper cell-independent antitumor activity of potent CD8+T cell epitope peptide vaccines is dependent upon CD40L. <i>Oncolmmunology</i> , 2013, 2, e27009.	2.1	3
65	Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression. <i>Journal of Immunology</i> , 2012, 189, 4674-4683.	0.4	219
66	Dendritic cells: Nearly 40 years later. <i>Immunologia (Barcelona, Spain: 1987)</i> , 2012, 31, 49-57.	0.1	0
67	The extradomain A of fibronectin (EDA) combined with poly(I:C) enhances the immune response to HIV-1 p24 protein and the protection against recombinant <i>Listeria monocytogenes</i> -Gag infection in the mouse model. <i>Vaccine</i> , 2012, 30, 2564-2569.	1.7	8
68	Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. <i>Vaccine</i> , 2012, 30, 2848-2858.	1.7	21
69	The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective <i>Salmonella</i> bacterins as vaccines in mice. <i>Veterinary Research</i> , 2012, 43, 31.	1.1	4
70	Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. <i>International Journal of Cancer</i> , 2012, 131, 641-651.	2.3	34
71	Abstract 4387: Antiviral and antitumoral effects of the anti-CTLA4 agent tremelimumab in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C virus (HCV) infection: Results from a phase II clinical trial. <i>Cancer Research</i> , 2012, 72, 4387-4387.	0.4	8
72	Contribution of IL-17-producing $\gamma\delta$ T cells to the efficacy of anticancer chemotherapy. <i>Journal of Experimental Medicine</i> , 2011, 208, 491-503.	4.2	303

#	ARTICLE	IF	CITATIONS
73	Therapeutic effect of a peptide inhibitor of TGF- β 2 on pulmonary fibrosis. <i>Cytokine</i> , 2011, 53, 327-333.	1.4	66
74	Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators. <i>Vaccine</i> , 2011, 29, 7130-7135.	1.7	56
75	Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. <i>Journal of Hepatology</i> , 2011, 54, 422-431.	1.8	68
76	Semblanza Francisco Borrás. <i>Inmunología (Barcelona, Spain: 1987)</i> , 2011, 30, 75-76.	0.1	0
77	Dynamic of nasal colonization by methicillin-resistant <i>Staphylococcus aureus</i> ST398 and ST1 after mupirocin treatment in a family in close contact with pigs. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2011, 34, e1-e7.	0.7	24
78	Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. <i>Hepatology</i> , 2011, 53, 23-31.	3.6	25
79	Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. <i>Hepatology</i> , 2011, 54, 28-37.	3.6	25
80	Contribution of IL-17 α -producing $\gamma\delta$ T cells to the efficacy of anticancer chemotherapy. <i>Journal of Experimental Medicine</i> , 2011, 208, 869-869.	4.2	6
81	Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors. <i>Cancer Research</i> , 2011, 71, 3214-3224.	0.4	63
82	The vaccine adjuvant extra domain A from fibronectin retains its proinflammatory properties when expressed in tobacco chloroplasts. <i>Planta</i> , 2010, 231, 977-990.	1.6	25
83	Skin Lesion Caused by ST398 and ST1 MRSA, Spain ¹ . <i>Emerging Infectious Diseases</i> , 2010, 16, 157-159.	2.0	38
84	A Peptide Inhibitor of FOXP3 Impairs Regulatory T Cell Activity and Improves Vaccine Efficacy in Mice. <i>Journal of Immunology</i> , 2010, 185, 5150-5159.	0.4	97
85	Poly(Anhydride) Nanoparticles Act as Active Th1 Adjuvants through Toll-Like Receptor Exploitation. <i>Vaccine Journal</i> , 2010, 17, 1356-1362.	3.2	107
86	Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice. <i>Vaccine</i> , 2010, 28, 5323-5331.	1.7	4
87	Tumor therapy in mice by using a tumor antigen linked to modulin peptides from <i>Staphylococcus epidermidis</i> . <i>Vaccine</i> , 2010, 28, 7146-7154.	1.7	8
88	Peptide inhibitors of transforming growth factor β 2 enhance the efficacy of antitumor immunotherapy. <i>International Journal of Cancer</i> , 2009, 125, 2614-2623.	2.3	62
89	Induction of Multiepitopic and Long-Lasting Immune Responses Against Tumour Antigens by Immunization with Peptides, DNA and Recombinant Adenoviruses Expressing Minigenes. <i>Scandinavian Journal of Immunology</i> , 2009, 69, 80-89.	1.3	12
90	Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. <i>Journal of Hepatology</i> , 2009, 51, 520-527.	1.8	21

#	ARTICLE	IF	CITATIONS
91	Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 19-29.	2.0	44
92	Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model. <i>Journal of Gene Medicine</i> , 2008, 10, 177-186.	1.4	15
93	Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C). <i>Journal of Viral Hepatitis</i> , 2008, 15, 782-789.	1.0	8
94	Vaccination Against Hepatitis C Virus With Dendritic Cells Transduced With an Adenovirus Encoding NS3 Protein. <i>Molecular Therapy</i> , 2008, 16, 210-217.	3.7	39
95	604 MONOCYTE-DERIVED DENDRITIC CELLS FROM HCV PATIENTS TRANSDUCED WITH A RECOMBINANT ADENOVIRUS EXPRESSING NS3 RETAIN THEIR FUNCTIONAL PROPERTIES WHEN STIMULATED WITH THE TLR3 LIGAND POLY(I:C). <i>Journal of Hepatology</i> , 2008, 48, S225.	1.8	0
96	612 THE EXTRA DOMAIN A FROM FIBRONECTIN (EDA) IMPROVES IMMUNOGENICITY OF NS3 PROTEIN IN A SEMLIKI FOREST VIRUS (SFV)-BASED VACCINE AGAINST HEPATITIS C. <i>Journal of Hepatology</i> , 2008, 48, S228.	1.8	0
97	In Vitro and In Vivo Down-Regulation of Regulatory T Cell Activity with a Peptide Inhibitor of TGF- β 1. <i>Journal of Immunology</i> , 2008, 181, 126-135.	0.4	63
98	A synthetic peptide from transforming growth factor- β 1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. <i>Cardiovascular Research</i> , 2008, 81, 601-609.	1.8	89
99	The Extra Domain A from Fibronectin Targets Antigens to TLR4-Expressing Cells and Induces Cytotoxic T Cell Responses In Vivo. <i>Journal of Immunology</i> , 2007, 178, 748-756.	0.4	89
100	Upregulation of Indoleamine 2,3-Dioxygenase in Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2007, 81, 3662-3666.	1.5	116
101	Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library. <i>Cytokine</i> , 2007, 39, 106-115.	1.4	69
102	Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. <i>Journal of Hepatology</i> , 2007, 47, 807-815.	1.8	69
103	Engineered promiscuous T helper peptides for the induction of immune responses. <i>Molecular Immunology</i> , 2007, 44, 2205-2212.	1.0	2
104	The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN γ . <i>International Journal of Cancer</i> , 2007, 121, 1282-1295.	2.3	16
105	Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. <i>Hepatology</i> , 2007, 45, 602-613.	3.6	84
106	Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection. <i>Journal of Pathology</i> , 2007, 213, 347-355.	2.1	7
107	Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40. <i>Antiviral Research</i> , 2007, 74, 25-35.	1.9	12
108	531 Expression of T regulatory cell-associated genes in the liver of patients with hepatitis C: Implications on viral chronification. <i>Journal of Hepatology</i> , 2006, 44, S198.	1.8	0

#	ARTICLE	IF	CITATIONS
109	Emergency Visits for Childhood Poisoning. <i>Pediatric Emergency Care</i> , 2006, 22, 334-338.	0.5	100
110	Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins. <i>Journal of Viral Hepatitis</i> , 2006, 13, 47-55.	1.0	18
111	CD137/CD137 Ligand in Tumor and Viral Immunotherapy. , 2006, , 117-135.		0
112	Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. <i>Journal of Hypertension</i> , 2005, 23, 625-632.	0.3	72
113	Topical Application of a Peptide Inhibitor of Transforming Growth Factor- β 1 Ameliorates Bleomycin-Induced Skin Fibrosis. <i>Journal of Investigative Dermatology</i> , 2005, 125, 450-455.	0.3	149
114	Modulation of Vaccine-Induced Immune Responses to Hepatitis C Virus in Rhesus Macaques by Altering Priming before Adenovirus Boosting. <i>Journal of Infectious Diseases</i> , 2005, 192, 920-929.	1.9	38
115	Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. <i>Vaccine</i> , 2005, 23, 1384-1392.	1.7	39
116	Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. <i>Vaccine</i> , 2005, 23, 3493-3499.	1.7	36
117	Carcinoembryonic Antigen as a Target to Induce Anti-Tumor Immune Responses. <i>Current Cancer Drug Targets</i> , 2004, 4, 443-454.	0.8	21
118	Identification and Characterization of a T-Helper Peptide from Carcinoembryonic Antigen. <i>Clinical Cancer Research</i> , 2004, 10, 2860-2867.	3.2	14
119	88 Identification of peptide inhibitors of transforming growth factor beta 1. <i>Journal of Hepatology</i> , 2004, 40, 30.	1.8	0
120	387 Protection against infection with an HCV-recombinant vaccinia virus by vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS4A protein. <i>Journal of Hepatology</i> , 2004, 40, 115-116.	1.8	1
121	A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage. <i>Hepatology</i> , 2003, 37, 461-470.	3.6	23
122	Protection against liver damage by cardiotrophin-1: a hepatocyte survival factor up-regulated in the regenerating liver in rats. <i>Gastroenterology</i> , 2003, 125, 192-201.	0.6	82
123	Expression of core and E1 proteins from hepatitis C virus in dendritic cells impairs T cell induction in vivo. <i>Journal of Hepatology</i> , 2003, 38, 15.	1.8	0
124	A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine induced liver damage: A possible mechanism for viral persistence. <i>Journal of Hepatology</i> , 2003, 38, 9.	1.8	0
125	Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. <i>Journal of Hepatology</i> , 2003, 38, 109.	1.8	0
126	A synthetic peptide from transforming growth factor β 2 type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. <i>Cytokine</i> , 2003, 22, 12-20.	1.4	114

#	ARTICLE	IF	CITATIONS
127	CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN- β -Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination. <i>Journal of Immunology</i> , 2003, 171, 5931-5939.	0.4	186
128	Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses. <i>Journal of Virology</i> , 2003, 77, 10862-10871.	1.5	127
129	Peptide Inhibitors of Hepatitis C Virus NS3 Protease. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 225-233.	0.3	6
130	Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses. <i>International Immunology</i> , 2003, 15, 691-699.	1.8	2
131	Abnormal Priming of CD4+ T Cells by Dendritic Cells Expressing Hepatitis C Virus Core and E1 Proteins. <i>Journal of Virology</i> , 2002, 76, 5062-5070.	1.5	141
132	Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. <i>Vaccine</i> , 2002, 21, 202-210.	1.7	57
133	Sun exposure and interaction with family history in risk of melanoma, Queensland, Australia. <i>International Journal of Cancer</i> , 2002, 97, 90-95.	2.3	44
134	Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen. <i>International Journal of Cancer</i> , 2002, 97, 58-63.	2.3	11
135	Inhibitory effect against polymerase and ribonuclease activities of HIV-reverse transcriptase of the aqueous leaf extract of <i>Terminalia triflora</i> . <i>Phytotherapy Research</i> , 2002, 16, 778-780.	2.8	10
136	T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. <i>Journal of Hepatology</i> , 2001, 35, 105-111.	1.8	30
137	Role of IL12 in genetic immunization against WHV-core antigen: induction of TH1 immune responses and protection against woodchuck hepatitis virus (WHV). <i>Journal of Hepatology</i> , 2001, 34, 225.	1.8	4
138	Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes. <i>Journal of Hepatology</i> , 2001, 34, 321-329.	1.8	19
139	Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. <i>European Journal of Immunology</i> , 2001, 31, 1780-1789.	1.6	77
140	Protection against Woodchuck Hepatitis Virus (WHV) Infection by Gene Gun Coimmunization with WHV Core and Interleukin-12. <i>Journal of Virology</i> , 2001, 75, 9068-9076.	1.5	32
141	Specific and general HLA-DR binding motifs: comparison of algorithms. <i>Human Immunology</i> , 2000, 61, 266-278.	1.2	50
142	Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes. <i>Journal of Hepatology</i> , 2000, 32, 45.	1.8	0
143	TH1 but not TH0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides. <i>Journal of Hepatology</i> , 2000, 32, 127.	1.8	0
144	Th1 but not Th0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides. <i>International Immunology</i> , 1999, 11, 2025-2034.	1.8	21

#	ARTICLE	IF	CITATIONS
145	Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. <i>Cancer Gene Therapy</i> , 1999, 6, 514-522.	2.2	79
146	Synthesis and anti-HIV-1 activities of new pyrimido[5,4-b]indoles. <i>Il Farmaco</i> , 1999, 54, 255-264.	0.9	16
147	Argentine plant extracts active against polymerase and ribonuclease H activities of HIV-1 reverse transcriptase. , 1999, 13, 206-209.		18
148	Transmission of Hepatitis C Virus Infection to Tree Shrews. <i>Virology</i> , 1998, 244, 513-520.	1.1	131
149	Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL). <i>Gene Therapy</i> , 1998, 5, 1622-1630.	2.3	23
150	Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. <i>Hepatology</i> , 1998, 28, 815-822.	3.6	80
151	Induction of cytotoxic lymphocytes against hepatitis C virus using a synthetic peptide from structural protein E1. <i>Journal of Hepatology</i> , 1998, 28, 51.	1.8	0
152	Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. <i>Gastroenterology</i> , 1997, 113, 1647-1653.	0.6	81
153	Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. <i>Journal of Hepatology</i> , 1997, 27, 726-737.	1.8	50
154	Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. <i>Hepatology</i> , 1997, 25, 470-477.	3.6	62
155	Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. <i>Hepatology</i> , 1997, 25, 470-477.	3.6	2
156	Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment. <i>Journal of Hepatology</i> , 1996, 25, 1-9.	1.8	40
157	Further Insights on the Inhibition of HIV Type 1 Infection <i>in Vitro</i> by CD4-Modified Synthetic Peptides Containing Phenylalanine. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1023-1030.	0.5	0
158	Fine Analysis of Immunoreactivity of V3 Peptides: Antibodies Specific for V3 Domain of Laboratory HIV Type 1 Strains Recognize Multiple V3 Sequences Synthesized from Field HIV Type 1 Isolates. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1671-1679.	0.5	2
159	Short Communication: B Cell Epitopes of HIV Type 1 p24 Capsid Protein: A Reassessment. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 519-525.	0.5	7
160	Simple strategy to induce antibodies of distinct specificity: Application to the mapping of gp120 and inhibition of HIV-1 infectivity. <i>European Journal of Immunology</i> , 1995, 25, 877-883.	1.6	48
161	Indoles and pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcriptase. <i>European Journal of Medicinal Chemistry</i> , 1995, 30, 963-971.	2.6	21
162	In vivo cytotoxic T-lymphocyte induction may take place via CD8+ T helper lymphocytes. <i>Research in Immunology</i> , 1995, 146, 35-44.	0.9	11

#	ARTICLE	IF	CITATIONS
163	Overcoming class II-linked non-responsiveness to hepatitis B vaccine. <i>Vaccine</i> , 1994, 12, 867-871.	1.7	15
164	Enhancement of peptide immunogenicity by insertion of a cathepsin B cleavage site between determinants recognized by B and T cells. <i>Research in Immunology</i> , 1993, 144, 257-262.	0.9	17
165	Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. <i>Cellular Immunology</i> , 1992, 141, 211-218.	1.4	45
166	Insights on the amino acid side-chain interactions of a synthetic T-cell determinant. <i>Biologicals</i> , 1991, 19, 187-190.	0.5	40
167	Induction of antibodies against a peptide hapten does not require covalent linkage between the hapten and a class II presentable T helper peptide. <i>European Journal of Immunology</i> , 1991, 21, 1555-1558.	1.6	40
168	Polarity of immunogens: implications for vaccine design. <i>European Journal of Immunology</i> , 1990, 20, 2363-2366.	1.6	57